Geode Capital Management LLC Buys 1,906 Shares of China Biologic Products, Inc. (CBPO)

Geode Capital Management LLC raised its stake in China Biologic Products, Inc. (NASDAQ:CBPO) by 15.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,309 shares of the biopharmaceutical company’s stock after purchasing an additional 1,906 shares during the period. Geode Capital Management LLC owned 0.05% of China Biologic Products worth $1,432,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after acquiring an additional 406,105 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in shares of China Biologic Products by 103.2% in the first quarter. Artisan Partners Limited Partnership now owns 395,578 shares of the biopharmaceutical company’s stock valued at $39,609,000 after acquiring an additional 200,868 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of China Biologic Products by 48.3% in the first quarter. Alliancebernstein L.P. now owns 555,525 shares of the biopharmaceutical company’s stock valued at $55,625,000 after acquiring an additional 180,970 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of China Biologic Products in the first quarter valued at about $14,257,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of China Biologic Products in the first quarter valued at about $14,257,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Geode Capital Management LLC Buys 1,906 Shares of China Biologic Products, Inc. (CBPO)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2017/09/17/china-biologic-products-inc-cbpo-shares-bought-by-geode-capital-management-llc.html.

China Biologic Products, Inc. (CBPO) opened at 90.81 on Friday. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 23.64 and a beta of 1.75. The company has a 50-day moving average of $93.66 and a 200-day moving average of $104.09. China Biologic Products, Inc. has a one year low of $88.25 and a one year high of $126.47.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.26 EPS. Equities research analysts expect that China Biologic Products, Inc. will post $4.96 EPS for the current fiscal year.

A number of equities research analysts have issued reports on CBPO shares. Goldman Sachs Group, Inc. (The) started coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating on the stock. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and set a $140.00 price objective on shares of China Biologic Products in a research note on Monday, June 12th. Finally, BidaskClub downgraded shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $132.00.

About China Biologic Products

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply